ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
New Study Highlights Promising Gene-Based Predictor of Prostate Cancer Risk
Test to be commercialized by Proactive Genomics, LLC In the past few years, novel research tools have emerged which scientist to systematically and objectively evaluate genetic variants in the genome. These new […]
